Home › Research › Drug development
Semaglutide Attenuates Neuroinflammation in Mice
Rausch DM, Ludwig MQ, Bentsen MA, Hansen SN, Secher A, Holst D, Moreno J, Das V et al.. bioRxiv, 2026-01-12
Topic: Inflammation, microglia and astrocytes
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown promise in preclinical models of neurodegeneration, with emerging evidence suggesting these effects may be driven by modulation of neuroinflammation. However, the cellular mechanisms underlying GLP-1 RA effects on neuroinflammation remain poorly understood. Here, using a mouse model of lipopolysaccharide-induced neuroinflammation, we investigated how semaglutide coordinates cellular responses to resolve neuroinflammation. We find that semaglutide prevents brain infiltration of neutrophils, excessive cytokine release, and suppresses neuroinflammation-associated transcriptional signatures specifically in microglia, endothelial cells, and a subset of pericytes. Mechanistically, we identify a subset of Glp1r -expressing neurons in the dorsal vagal complex that, upon semaglutide treatment, regulate genes involved in anti-inflammatory signaling. Semaglutide-modulated pathways overlap with inflammatory signatures found in human neurodegenerative diseases, including Alzheimer’s disease, suggesting broad relevance for conditions involving neuroinflammation. Together, these findings reveal how GLP-1R signaling orchestrates resolution of neuroinflammation through coordinated multi-cellular programs.
Key findings
- Together, these findings reveal how GLP-1R signaling orchestrates resolution of neuroinflammation through coordinated multi-cellular programs.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 21 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported and randomised / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 13 of the 62 points we could judge it on, which is 21 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (bioRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “mice”) — scores zero |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 13 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 13 of the 62 points we could judge it on is 21 out of 100. |
| Total | 21 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Rausch, D. M., Ludwig, M. Q., Bentsen, M. A., Hansen, S. N., Secher, A., Holst, D., et al. (2026). Semaglutide Attenuates Neuroinflammation in Mice. bioRxiv. https://doi.org/10.64898/2026.01.10.698763
Vancouver
Rausch DM, Ludwig MQ, Bentsen MA, Hansen SN, Secher A, Holst D, et al. Semaglutide Attenuates Neuroinflammation in Mice. bioRxiv. 2026. doi:10.64898/2026.01.10.698763.
BibTeX
@article{rausch2026-a2d21860,
author = {Rausch, D. M. and Ludwig, M. Q. and Bentsen, M. A. and Hansen, S. N. and Secher, A. and Holst, D. and Moreno, J. and Das, V. and others},
title = {{Semaglutide Attenuates Neuroinflammation in Mice}},
journal = {bioRxiv},
year = {2026},
doi = {10.64898/2026.01.10.698763},
url = {https://doi.org/10.64898/2026.01.10.698763}
}
Related studies in Drug development
Also tagged “expressed”
384 studies in the library carry the topic tag “expressed”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 384 tagged studies.